Rosie Bradley on early-stage breast cancer treatment

Rosie Bradley (Oxford Population Health, University of Oxford, Oxford, UK) discusses her Article on aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression.

Read the full article:

Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression (thelancet.com/journals/lanonc/article/PIIS1470…)00758-0/fulltext)

Tell us what you thought about this episode (buzzsprout.com/1391338/fan_mail/new)

Continue this conversation on social!

Follow us today at...

thelancet.bsky.social

instagram.com/thelancetgroup

facebook.com/thelancetmedicaljournal

linkedIn.com/company/the-lancet (linkedin.com/company/the-lancet)

youtube.com/thelancettv